While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

The FDA is becoming deeply compromised and increasingly at risk of being permanently transformed in ways contrary to its ...

Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.

In this episode of Denatured presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, Mayo Clinic; Marilyn ...

The difference between a job and a career is what you walk away with when it ends. Here's how to evaluate if your role and ...

Steven A. Grossman, JD, is President of HPS Group, LLC, a policy and regulatory consulting firm, and author of “FDA Matters: ...

Also on Thursday, Zealand held its Capital Markets Day in London, outlining the strategy for its weight management franchise in the near-term, including launching five products by 2030.

Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...